binding assay with respect to their direct interaction with PXR LBD. Significantly, some of these compounds -ketoconazole, coumesterol, metformin-inhibit PXR transactivation via interference with PXR coactivators or through binding to the AF-2 domain of PXR independently of PXR LBD. It has been recently hypothesized that ketoconazole may affect PXR transcriptional regulation by binding to two potential and distinct "antagonistbinding pockets" outside the ligand binding pocket (2) . Nevertheless, no PXR antagonist has been described to exert its effect within the bulky PXR binding pocket so far, which brings into question the ability of a smallmolecule antagonist to interact with PXR LBD.
Several studies have indicated that a number of cellular signaling pathways affected by small-molecule compounds modulate the function of PXR via a posttranslational phosphorylation-mediated mechanism with respect to both basal and ligand-activated transactivation. PXR has been found to be phosphorylated in three ways: by the protein kinase A (PKA) and the protein kinase C (PKC) signaling pathways, by cyclin-dependent kinases 2 (CDK2) and 5 (CDK5), and by p70 S6K, a downstream kinase of the PI3K-Akt pathway (3).
In the current issue of the Journal of Pharmacological Sciences, Deng et al. show evidence for the first time that trans-resveratrol (RES), a natural stilbenoid, attenuates the rifampicin-inducible expression of CYP3A4 through PXR (4) . As a high concentration of RES is found in red wine, in red grapes, and in other fruits and since RES is present in numerous antioxidative and antiaging nutritional supplements, this finding may have significant clinical consequences in terms of drug-dietary supplement and food-drug interactions.
RES has been found to competitively inhibit cAMPdegrading phosphodiesterases, leading to elevated cAMP levels. The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca 2+ levels, activates the CamKKb-AMPK pathway as well as increases activity of SIRT1 deacetylase. In addition, numerous other cellular effects of RES have been reported in the literature, including controlling cellular calcium homeostasis, modulation of the transcription factors NF-kB, Nrf2, and topoisomerase inhibition.
Therefore, a link can be hypothesized between the effects, on the one hand, of RES on cellular cAMP and Ca 2+ levels or on the other hand, PKA and PKC signaling activation as the reason for the consequent suppression of PXR activity due to the phosphorylation of PXR via the signaling cascades. Obviously, further evidence is needed. RES may also indirectly influence PXR activity via NF-kB inhibition or via SIRT1 signaling since PXR interferes reciprocally with the cascades.
Using a Time Resolved-FRET based ligand binding cell-independent in vitro assay with recombinant human PXR, we observed a significant interaction of RES with the PXR ligand binding pocket within the concentration range of 0.1 -20 mM. Therefore, we can conclude based on current knowledge that RES may i) interact with the PXR LBD domain and/or ii) activate some protein kinase signaling cascades to suppress PXR activity in regulation of its target genes.
There is growing consensus that PXR inhibition may be an important mechanism in reversing cancer drug resistance and tumor growth, eliminating unwanted PXR-mediated drug-drug interactions, and alleviating PXR-induced hepatic steatosis. Thus new selective and non-toxic PXR antagonists are being investigated intensively. Primarily, however, there is urgent need for an increased understanding of the mechanisms of PXR antagonisms.
